

EXECUTIVE SUMMARY

Formalin and Formaldehyde in Healthcare: Occupational Risks, Regulatory Obligations, and Closed-System Solutions

Formalin, the liquid form of formaldehyde used to preserve tissue samples, remains essential to diagnostic pathology. It is also a volatile, toxic substance classified as a Category 1B carcinogen under both EU and UK regulations. Its unmatched performance as a tissue fixative means that formalin will continue to be used in healthcare settings for the foreseeable future. However, its hazardous properties place clear legal obligations on every employer whose staff handle it.


This paper examines the evidence on formaldehyde exposure in healthcare settings and its implications for worker safety and regulatory compliance. The findings point to a consistent picture, a clear legal framework, and a proven solution.

The occupational health evidence

Healthcare workers who handle formalin regularly, including operating theatre nurses, pathology technicians, and laboratory staff, are routinely exposed to formaldehyde vapour at concentrations that cause measurable harm. Reported symptoms include eye and respiratory irritation, headaches, allergic rhinitis, asthma, and contact dermatitis (ATSDR, 2010). These symptoms are significantly more prevalent among exposed workers than among the general population. At higher or prolonged exposures, formaldehyde's classification as a carcinogen is supported by epidemiological evidence linking occupational exposure to cancers of the upper respiratory tract (Fan et al., 2025). Crucially, adverse effects are observed even when measured exposures fall within regulatory limits, challenging the assumption that compliance with threshold values equates to protection.

The regulatory and legal position

European and UK law establishes a hierarchy of control that prioritises elimination of exposure at source. The EU Carcinogens, Mutagens and Reprotoxic Substances Directive (CMRD), updated in 2022, explicitly requires the use of closed systems to protect workers from carcinogenic substances wherever technically feasible. The UK Control of Substances Hazardous to Health (COSHH) Regulations



impose equivalent duties. Personal protective equipment and ventilation, while useful as supplementary measures, sit at the bottom of the hierarchy of control and cannot substitute for elimination at source. Adoption of closed-system specimen handling is not merely advisable; it is rapidly becoming the standard of care that employers are legally required to meet.

The evidence for closed-system interventions

Closed-system specimen containers meet EU & UK regulatory requirements by encapsulating formalin and preventing vapour release during handling. Evidence from a twenty-year monitoring programme at Careggi University Hospital in Florence demonstrates that adoption of closed systems can reduce airborne formaldehyde concentrations by over 90%, achieving exposure levels that are effectively negligible from an occupational health perspective (Dugheri et al., 2020). Importantly, these reductions are achieved without compromising diagnostic quality or workflow efficiency.

Choosing the right closed system

Not all closed-system containers are equivalent. The most effective design uses containers in which formalin is stored in a sealed reservoir within the lid and released only after the specimen has been secured inside the container. This single-action, press-release mechanism prevents vapour release at the point of specimen collection and during routine handling, eliminates the risk of suboptimal fixation performance with saline-prefilled alternatives and requires no specialist training. Valid CE marking under IVDR (EU 2017/746), robust seal integrity, a range of container sizes to match specimen volume, and practical accessibility for laboratory processing should all form part of any procurement and implementation assessment.

Conclusion

For healthcare institutions still using open containers, the availability of proven closed-system alternatives has significant compliance implications. The question is no longer whether closed-system specimen handling is necessary, but how quickly it can be implemented. Continued reliance on open containers, ventilation, and inadequate PPE is increasingly difficult to defend, both as a matter of worker safety and of regulatory compliance. Healthcare institutions that delay adoption expose their staff to avoidable harm and themselves to potential legal liability. Closed-system technologies enable providers to meet their duty of care to staff, satisfy regulatory requirements, and maintain the diagnostic standards on which patient care depends.

References

- Agency for Toxic Substances and Disease Registry (ATSDR) (1999) *Toxicological profile for formaldehyde*. Addendum published 2010. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention.
- Dugheri, S., Massi, D., Mucci, N., Berti, N., Cappelli, G. and Arcangeli, G. (2020) 'How improvements in monitoring and safety practices lowered airborne formaldehyde concentrations at an Italian university hospital: a summary of 20 years of experience', *Arhiv za Higijenu Rada i Toksikologiju*, 71(3), pp. 178 to 189.
- European Parliament and Council of the European Union (2017) *Regulation (EU) 2017/746 on in vitro diagnostic medical devices*. *Official Journal of the European Union*, L 117, 5 May.
- Fan, H.Y., Lin, J.P., Yang, T.A. and Tsao, Y.C. (2025) 'Health effects of low dose formaldehyde exposure: a cross sectional study in occupational settings', *International Journal of Occupational Medicine and Environmental Health*, 38(3), pp. 236 to 248.

This white paper was prepared by the European Biosafety Network with research and editorial support from independent contributors. Its production was supported by industry. Please contact: josh.cobb@europeanbiosafetynetwork.eu for more information.